



Genetic and environmental factors on the relation of lung function and arterial stiffness



David Laszlo Tarnoki ^{a,*}, Adam Domonkos Tarnoki ^{a,m},
Zsofia Lazar ^b, Emanuela Medda ^c, Levente Littvay ^d,
Rodolfo Cotichini ^c, Corrado Fagnani ^c, Maria Antonietta Stazi ^c,
Lorenza Nisticó ^c, Pierleone Lucatelli ^e, Emanuele Boatta ^e,
Chiara Zini ^e, Fabrizio Fanelli ^e, Claudio Baracchini ^f,
Giorgio Meneghetti ^f, Gyorgy Jermendy ^g, István Préda ^{h,i},
Róbert Gábor Kiss ^{h,i}, Kinga Karlinger ^a, Agnes Lannert ^j,
Giuseppe Schillaci ^k, Andrea Agnes Molnar ^{h,i}, Zsolt Garami ^l,
Viktor Berczi ^a, Ildiko Horvath ^b

^a Department of Radiology and Oncotherapy, Semmelweis University, 78/a Ulloi Street, Budapest 1082, Hungary

^b Department of Pulmonology, Semmelweis University, 1/C Diós árok, 1125 Budapest, Hungary

^c Istituto Superiore Di Sanità, National Centre for Epidemiology, Surveillance and Health Promotion, Genetic Epidemiology Unit, Italian Twin Registry, Viale Regina Elena 299, 00161 Roma, Italy

^d Central European University, 9 Nádor Street, 1051 Budapest, Hungary

^e Vascular and Interventional Radiology Unit, Department of Radiological Sciences, Sapienza University of Rome, Viale Regina Elena 324, 00161 Roma, Italy

^f Department of Neurosciences, School of Medicine, University of Padua, Via Giustiniani 5, 35128 Padova, Italy

^g Bajcsy Zsilinszky Hospital, 3rd Department of Internal Medicine, 89-91 Maglodi Street, Budapest 1106, Hungary

^h Research Group for Inflammation Biology and Immunogenomics of Hungarian Academy of Sciences and Semmelweis University, 44 Róbert Károlyi krt, Budapest 1134, Hungary

* Corresponding author. Tel.: +36 30 3687843; fax: +36 1 2780367.

E-mail addresses: tarnoki4@gmail.com (D.L. Tarnoki), tarnoki2@gmail.com (A.D. Tarnoki), zsofia.lazar@yahoo.com (Z. Lazar), emanuela.medda@iss.it (E. Medda), levi@littvay.com (L. Littvay), rodolfo.cotichini@iss.it (R. Cotichini), corrado.fagnani@iss.it (C. Fagnani), antonia.stazi@iss.it (M.A. Stazi), lorenza.nistico@iss.it (L. Nisticó), pierleone.lucatelli@gmail.com (P. Lucatelli), emanuele.boatta@yahoo.it (E. Boatta), zini.chiara@gmail.com (C. Zini), fabrizio.fanelli@uniroma1.it (F. Fanelli), claudiobaracchini@tin.it (C. Baracchini), giorgio.meneghetti@unipd.it (G. Meneghetti), gyjermendy@mail.datanet.hu (G. Jermendy), predadr@gmail.com (I. Préda), robertgaborkiss@gmail.com (R.G. Kiss), kinga.karling@gmail.com (K. Karlinger), zanzarita@freemail.hu (A. Lannert), skill@unipg.it (G. Schillaci), molnandi@gmail.com (A.A. Molnar), ZGarami@tmhs.org (Z. Garami), berczi@hotmail.com (V. Berczi), kiss.horvath@t-online.hu (I. Horvath).

^m Each author contributed equally to this paper.

ⁱ Department of Cardiology, Military Hospital – State Health Center, 44 Róbert Károly krt, Budapest 1134, Hungary

^j Semmelweis University, School of Pharmacy, 26 Ulloi Street, Budapest 1085, Hungary

^k Unit of Internal Medicine, Department of Medicine, University of Perugia at Terni, Piazzale Tristano di Joannuccio 1, 05100 Terni, Italy

^l The Methodist Hospital, Methodist DeBakey Heart & Vascular Center, 6565 Fannin Street, Houston, TX 77030, USA

Received 9 May 2012; accepted 7 February 2013

Available online 6 March 2013

KEYWORDS

Pulmonary function test;
Forced vital capacity;
Augmentation index;
Pulse wave velocity;
Genetics

Summary

Background: An association between reduced lung function and increased cardiovascular risk has been reported, but the underlying mechanisms are unknown. The aim of this study was to assess the heritability of lung function and to estimate its genetic association with arterial stiffness.

Methods: 150 monozygotic and 42 dizygotic healthy Hungarian and American Caucasian twin pairs (age 43 ± 17 years) underwent spirometry (forced vital capacity/FVC/, forced expiratory volume in 1 s/FEV₁/; MIR Minispir, USA); and their brachial and central augmentation indices (Aix), and aortic pulse wave velocity (PWV) were measured by oscillometric Arteriograph (Colson, Colson Med Ltd, Budapest, Hungary). Phenotypic correlations and bivariate Cholesky decomposition models were applied.

Results: Age-, sex-, country- and smoking-adjusted heritability of FEV₁, percent predicted FEV₁, FVC and percent predicted FVC were 73% (95% confidence interval /CI/: 45–85%), 28% (95% CI: 0–67%), 68% (95% CI: 20–81%) and 45% (95% CI: 0–66%), respectively. Measured and percent predicted FVC and FEV₁ values showed no significant phenotypic correlations with Aix or aortic PWV, except for phenotypic twin correlations between measured FEV₁, FVC with brachial or aortic augmentation indices which ranged between –0.12 and –0.17. No genetic covariance between lung function and arterial stiffness was found.

Conclusions: Lung function is heritable and the measured FVC and FEV are phenotypically, but not genetically, associated with augmentation index, a measure of wave reflection. This relationship may in turn reveal further associations leading to a better mechanistic understanding of vascular changes in various airway diseases.

© 2013 Elsevier Ltd. All rights reserved.

Introduction

Heritability of lung function has been investigated in twin and family studies, with discordant results. In such studies, heritability of forced expiratory volume in 1 s (FEV₁) ranged between 10% and 77% and that of forced vital capacity (FVC) ranged between 26% and 91%. Environmental factors could explain a modest part of the variance in most of the studies.^{1–5} Lung function also depends on gender.⁶ Age differences also influence the variance of lung function.³ A longitudinal study of twins found that the heritability of FEV₁ and FVC among never smoking female twins do not change remarkably (32% and 36% for FEV₁, 41% and 37% for FVC at baseline and at 3-year follow-up, respectively).⁴ Genetic factors seem to modestly contribute to lung function variance as demonstrated in a longitudinal study.⁷

The relationship between impaired lung function and atherosclerosis or cardiovascular morbidity and mortality has been investigated by several authors.^{8,9} Higher arterial stiffness is associated with poorer lung function when

adjusted for age, sex, and ethnic group.¹⁰ Elevated plasma levels of inflammatory markers may partially explain the increased cardiovascular risk among men with low FVC.¹¹ Obviously, smoking also contributes to the association between pulmonary function and coronary heart disease.¹² French epidemiological data showed that, even in healthy men, there is a relationship between pulmonary function and arterial stiffness.¹³ To our knowledge, no study has ever investigated the genetic influence on the lung function-arterial stiffness relationship. In order to assess this association, twin study modeling is the most appropriate method. By comparing identical with non-identical twins, twin studies provide information on the relative contribution of genes and environment, and how the two interact.

The aim of our study was to assess the heritability of lung function, the phenotypic correlations between pulmonary function (FEV₁, FVC) and arterial stiffness measures, and furthermore, to determine whether there is a shared genetic relation between lung function and arterial stiffness.

Methods and materials

Subjects and study design

192 Hungarian and American healthy adult twin pairs (150 monozygotic [MZ] and 42 dizygotic [DZ]; age 43 ± 17 years (mean \pm standard deviation) were recruited in this classic twin study. Exclusion criteria were chronic respiratory disease, pregnancy, ethnicity other than Caucasian, acute infection within three weeks of measurement or foreseeable lack of compliance with test procedures. Zygosity was assigned according to a seven-part self-reported response.¹⁴ Studies were approved by local ethical committees (Institutional Review Board committee names and project approval numbers: Semmelweis University Regional and Institutional Committee of Science and Research Ethics, 29/2009; Twins Days Festival Ethical Board, 1/2009) and all study subjects gave informed consent prior to entering the study.

Anthropometric, respiratory and vascular measurements were obtained at two Hungarian twin festivals (Agfalva and Szigethalom), in two Hungarian hospitals and at the Twins Days Festival in the USA (Twinsburg, OH) in 2009 and 2010.

Anthropometric data

Body mass index (BMI) was measured by a clinically validated OMRON BF500 body consistency monitor (Omron Healthcare Ltd., Kyoto, Japan). Current height was verified simultaneously.

Pulmonary function measurement

Lung function was assessed by dynamic spirometry (Minispir Waukesha, WI, USA). The spirometer was calibrated daily using a 1-L syringe. The maneuvers were performed with the subject standing while wearing nose clips. The largest FEV₁ and the largest FVC from among all acceptable maneuvers were used in this analysis. FVC and FEV₁ measurements were performed in accordance with guidelines recommended by the American Thoracic Society.¹⁵ Lung function variables were expressed in absolute (measured) values and as a percentage of predicted values (based on the subject's age, height, sex), using the reference values recommended by the ERS¹⁶ and ECCS93 reference equation values.¹⁷

Arterial stiffness test

Aortic pulse wave velocity (PWV_{ao}) as a measure of arterial stiffness and brachial (Alx_{bra}) and aortic augmentation indices (Alx_{ao}) as measures of the arterial waveform were assessed by a clinically validated oscillometric device^{18,19} (TensioMed Arteriograph, TensioMed Ltd., Hungary, software version 1.10.1.1.), calculating arterial stiffness parameters from oscillometrically recorded pressure waves of the brachial artery (pulse wave analysis), in supine position. PWV_{ao} is widely recognized as a direct marker of arterial stiffness^{20,21} and inversely related to arterial distensibility; it is calculated by the formula:

$PWV_{ao} = \text{distance (m)}/\text{transit time (sec)}$. PWV_{ao} is correlated with cardiovascular risk factors²² and it is a strong vascular risk factor for prediction of mortality in the elderly²³ and in the general population.²⁴ Dividing the augmentation pressure (difference between the second and first systolic peaks, P₂–P₁) by the pulse pressure gives the augmentation index, which is an indirect marker of endothelial dysfunction. The augmentation index is being used more and more frequently in studies as a parameter of peripheral vascular resistance and wave reflection.^{25,26}

Study subjects were evaluated by the same researchers in order to decrease inter-observer variability and in accordance with guidelines recommended by the European Society of Cardiology.²⁷ The PWV is calculated from each pulse wave from the suprasystolic measurement, and the results are compared. The standard deviation of the PWV values is taken as a measure of good correlation, or similarity, between them. The software (TensioMed) accepts the measurements as good quality under SD = 1.0. Only the mean value of the best measurement (if automatic quality control showed less than 1.0 standard deviation for PWV_{ao}) was taken into consideration during the analysis. All subjects were restricted from smoking for 3 h, from eating for 1 h, and from drinking alcohol or coffee for 10 h prior to measurements. Adherence to these restrictions was ascertained by querying the subject.

Statistical analysis

Descriptive analysis (mean \pm standard deviation for continuous variables, percentage for categorical variables) for BMI, FEV₁, FVC values, and vascular parameters was conducted using SPSS (SPSS 17.0 for Windows; SPSS, Chicago, IL). Differences between genders, zygosity and countries were calculated using independent-sample *t*-tests. *P* value <0.05 was considered significant. All analyzes were corrected for age, gender, country (significant effect of country, *p* < 0.05) and smoking (the phenotypic correlations were also calculated unadjusted to smoking). Smoking was adjusted according to two groups (never smokers and ex-smokers with a quitting period of at least one year and <5 pack year; and ex-smokers with >5 pack year and active smokers; 1 pack year is defined as smoking 1 pack of cigarettes daily for at least one year). Heritability estimates were determined based on the consideration that greater levels of MZ than DZ within pair similarity indicate a genetic influence on a phenotype, while similarity of co-twin correlations suggests that the variance is due to shared environmental factors. Three general sources of variance are calculated: (i) additive genetic factors or heritability (A) which represents the effects due to genes at multiple loci or multiple alleles at one locus; (ii) common environmental variance (C), which estimates the contribution of the common family environment of both twins (familiar socialization, diet, exposure to high levels of air pollution, parental smoking, shared womb, etc.); and (iii) nonshared environmental variance (E), which represents the effects that apply only to each individual twin and all sources of unique experiences and exposures that cause within-pair differences (e.g., discordance for smoking, differences in illnesses and occupational exposures). Structural equation modeling was performed using the

Mplus Version 6.1 (Muthén&Muthén) weighted least squares estimation due to the categorical variable of interest.²⁸ Empirical confidence intervals were calculated with a Bollen-Stine Bootstrap.²⁹ Univariate quantitative genetic modeling was performed to decompose the phenotypic variance of the considered parameters into heritability (A), shared (C), and unshared (E) environmental effects (ACE analysis).³⁰ Chi-square model fit *p*-values are presented where the desired results show insignificant model misfit. Instead of a covariance matrix, the estimation procedure used the raw data matrix. Given the small sample size, no component was fixed to 0 in the model.

A bivariate Cholesky decomposition was used to derive the magnitude of covariation between the investigated respiratory function and arterial stiffness phenotypes and to estimate what proportion of this correlation is attributable to common underlying genetic and environmental factors. In order to estimate the amount of overlap between genes or environment that influences the two parameters, genetic and environmental correlations between those phenotypes were calculated.

Results

Clinical characteristics and measures

Table 1 presents clinical characteristics of the sample by zygosity, sex and country. Opposite-sex twin pairs were excluded as their inclusion could bias the heritability estimates upward if gender-specific or X chromosome effects are present. A significant difference between males and females was observed concerning the arterial stiffness, BMI, measured FEV₁ and FVC (*p* < 0.05 for all). A significant difference in the rate of current and ex-smokers was detected across countries (*p* < 0.001 for both). Smoking years were higher in dizygotic twins than in monozygotic subjects (*p* < 0.05). Significant differences were observed in pulmonary function parameters concerning zygosity (*p* < 0.05) except for percent predicted FEV₁. Hungarian twins had significantly higher lung function values (*p* < 0.001 for FVC and *p* < 0.05 for FEV₁, respectively) compared to the Americans.

Heritability analysis of pulmonary function and arterial stiffness

Age-, sex-, country- and smoking-adjusted genetic and environmental variance, estimated with ACE analysis, and demonstrated 95% confidence intervals (CI), are shown in Table 2. Accordingly, genetic factors appear to contribute, at least in part, to the pulmonary function and arterial stiffness parameters, as the MZ twins had higher intrapair correlation compared to that of DZ twins. Models had a good fit.

Phenotypic twin correlations between pulmonary function and arterial stiffness

Table 3 presents phenotypic twin correlations, the correlations between phenotypes within the same individuals,

for FEV₁, FVC and arterial stiffness considering age, family, sex and country as covariates with or without smoking adjustment. Phenotypic correlation ranged between −0.12 and −0.17 (*p* < 0.05) between measured pulmonary function values and both brachial and aortic augmentation indices, suggesting that better measured lung function corresponds to lower Alx values. Additionally, FVC and FEV₁ values showed no significant phenotypic correlations with Alx or aortic PWV. The estimated ACE model confirmed the role of genetic factors on lung function and arterial stiffness phenotypes; in addition, significant low phenotypic correlations were estimated between some pulmonary function and arterial stiffness measures, therefore, a possible genetic covariance of FEV₁, FVC and Alx can be estimated by the bivariate Cholesky decomposition model. Measured and percent predicted FVC and FEV₁ values showed no significant phenotypic correlation with aortic PWV; therefore, the influence of common genetic and environmental factors on those relationships were not investigated.

Genetic covariance of FEV₁, FVC, brachial and aortic augmentation indices

Standardized genetic, common and unique environmental components of the covariance were calculated in the investigated measures by the bivariate Cholesky decomposition model. Additive genetic components showed no significant influence for the covariance between lung function values and augmentation indices (therefore, data are not shown).

Discussion

To our knowledge, this is the first study that investigates the relative contribution of genetic and environmental factors to the relation between lung function and arterial stiffness in a relatively large twin sample. This study demonstrates that the heritability of lung function is high for observed absolute values and moderate for percent predicted values, and a significant negative low phenotypic correlation exists between measured FEV₁, FVC and augmentation indices. No significant phenotypic correlation was estimated between lung function parameters and aortic PWV. No genetic covariance was found between FEV₁, FVC and augmentation index.

Our findings concerning the heritability of lung function and vascular stiffness are in line with the literature.^{1–3,30–37} In our population-based sample of twins, genetic effects accounted for 28–73% of the variability of lung function. Two twin studies showed that additive genetic effects on FEV₁ accounted for 61%, and 67% of the total variation; however, the mean age was higher with respect to our population.^{1,3} Hubert and co-workers reported slightly higher heritability results than our data, but their study population contained only adult (42–56 years) male twins.² The genetic variance accounted for 50–58% for the brachial Alx, aortic Alx and PWV, similarly to other studies with reported heritabilities of 37–53%.^{30–34}

Significant negative phenotypic correlation was found between FEV₁, FVC and Alx (but not with aortic PWV) which

Table 1 Clinical characteristics and measures according to zygosity, gender and country.

	Total	Zygosity		Gender		Country	
		Monozygotic	Dizygotic	Male	Female	Hungarian	American
Subjects, <i>n</i>	384	300	84	88	296	290	94
Monozygotic:dizygotic, <i>n</i>	300:84	N/A	N/A	70:18	230:66	212:78	88:6
Age, years	43 ± 17	42 ± 17 [%]	48 ± 14 [%]	43 ± 17	44 ± 17	43 ± 17	46 ± 17
FVC, % predicted	97.4 ± 16.0	96.1 ± 16.3 [%]	100.6 ± 14.9 [%]	99.3 ± 16.1	96.7 ± 16.0	100.0 ± 15.0 [§]	89.1 ± 16.2 [§]
FEV ₁ , % predicted	99.3 ± 15.5	98.8 ± 15.7	100.5 ± 15.0	99.1 ± 17.5	99.2 ± 14.8	100.3 ± 14.9 [#]	95.9 ± 16.9 [#]
FEV ₁ , l	3.0 ± 0.8	2.9 ± 0.8 [%]	3.1 ± 0.9 [%]	3.8 ± 0.8 [§]	2.7 ± 0.6 [§]	3.1 ± 0.8 [§]	2.7 ± 0.8 [§]
FVC, l	3.5 ± 1.0	3.4 ± 1.0 [‡]	3.8 ± 1.1 [‡]	4.6 ± 1.0 [§]	3.2 ± 0.7 [§]	3.7 ± 1.0 [§]	3.0 ± 0.9 [§]
Brachial Alx, %	-29.6 ± 32	-30.5 ± 33	-26.0 ± 29	-43.3 ± 26 [†]	-25.6 ± 33 [†]	-29.0 ± 32	-31.3 ± 30
Central Alx, %	22.5 ± 16	22.0 ± 16	24.2 ± 14	15.6 ± 13 [†]	24.5 ± 16 [†]	22.7 ± 16	21.8 ± 15
Aortic PWV, m/s	8.6 ± 2.5	8.4 ± 2.4	9.3 ± 2.4	8.1 ± 2.0 [†]	8.8 ± 2.6 [†]	8.7 ± 2.5	8.6 ± 2.4
BMI, kg/m ²	25.8 ± 5.5	25.6 ± 5.5	26.6 ± 5.4	27.0 ± 4.5 [†]	25.6 ± 5.8 [†]	25.4 ± 5.2	27.4 ± 6.2
Never smokers, %	70.3	71.4	66.3	67.4	71.1	70.5	69.5
Ex smokers, %	17.1	16.2	20.5	19.1	16.5	13.7 [§]	27.4 [§]
Current smokers, %	12.6	12.5	13.3	13.5	12.4	15.8 [§]	3.2 [§]
Smoking years	4.3 ± 9.7	3.5 ± 8.3 [%]	7.3 ± 13.3 [%]	5.1 ± 10.4	4.1 ± 9.4	4.3 ± 9.5	4.3 ± 10.2

Mean ± standard deviation. FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 s; Alx, augmentation index; PWV, pulse wave velocity; BMI, body mass index.

[%]Monozygotic vs dizygotic *p* < 0.05.

[‡]Monozygotic vs dizygotic *p* < 0.005.

[†]Male vs female *p* < 0.05.

[§]Male vs female *p* < 0.001.

Hungarian vs American *p* = 0.052.

[§] Hungarian vs American *p* < 0.001.

[#]Hungarian vs American *p* < 0.05.

Table 2 Age, gender, country and smoking adjusted genetic and environmental variance component parameter estimates and 95% confidence intervals of the best-fitting univariate ACE models with *p* value of model fit.

Measure	A	C	E	Model fit (<i>p</i> value)
FVC, % predicted	0.45 (0.00–0.66)	0.14 (0.00–0.56)	0.41 (0.31–0.52)	0.58
FEV ₁ , % predicted	0.28 (0.00–0.67)	0.31 (0.00–0.59)	0.41 (0.27–0.55)	0.49
FVC, l	0.68 (0.20–0.81)	0.08 (0.00–0.55)	0.24 (0.17–0.32)	0.49
FEV ₁ , l	0.73 (0.45–0.85)	0.00 (0.00–0.55)	0.26 (0.17–0.37)	0.26
Aortic Alx, %	0.58 (0.10–0.75)	0.10 (0.00–0.57)	0.32 (0.24–0.44)	0.12
Brachial Alx, %	0.55 (0.08–0.74)	0.13 (0.00–0.57)	0.33 (0.24–0.45)	0.17
Aortic PWV, m/s	0.50 (0.25–0.68)	0.00 (0.00–0.00)	0.50 (0.33–0.73)	0.0001

A, indicates heritability; C, shared environmental variance component; E, unique environmental variance component; Model fit, *p* value of Chi-square test of Model fit; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 s; Alx, augmentation index; PWV, pulse wave velocity.

indicates that impaired lung function is associated with increased peripheral vascular resistance and wave reflection, but not with aortic distensibility characterized by aortic PWV. The association of cardiovascular and respiratory system has been previously hypothesized because increased cardiovascular morbidity and mortality was observed in patients with impaired lung function.^{8–10} However, novel hemodynamic measurements such as oscillometric arterial stiffness assessment, which is included in our study, had not been previously performed. Our study showed that there is a phenotypic but no genetic relationship between lung function and peripheral vascular resistance (wave reflection). Alx is accepted as measure of wave reflection³⁰ and it is closely correlated with the cardiovascular risk and an independent predictor of mortality in patients with end-stage renal disease.²⁶ Arterial stiffness was also correlated with the quality of life in older people.³⁵

Although we report data collected from a healthy population, the relationship between arterial stiffness and respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and bronchial asthma, might also be of clinical relevance and has in fact been investigated previously.^{36–44} In particular, COPD and emphysema patients are at increased risk for cardiovascular morbidity and mortality, associated with endothelial dysfunction, arterial stiffness and atherogenesis, independently of tobacco

smoke exposure.^{36–40} The key elements causing an early subclinical cardiovascular involvement in COPD patients may include systemic and abnormal lung inflammation, hypoxia, oxidative stress, alterations in levels of matrix metalloproteinases and the functionality of endothelial nitric oxide synthase.^{41,42} Emphysema severity is associated with arterial stiffness in COPD patients, which may be attributable to similar pathophysiological processes within the lung and arteries.⁴³ Significant correlations between arterial stiffness and FEV₁ were reported in asthmatic patients, suggesting the presence of a common systemic process, most likely an inflammatory pathway, involving both the cardiovascular and respiratory systems.⁴⁴

Based on our results, the same non-genetic factors may play a role in lung function and endothelial function in healthy individuals.^{11–13} Due to the possible non-genetic (although weak) link between impaired lung function and vascular resistance, as a possible clinical consequence of our study, early screening of augmentation index in patients with reduced lung function is warranted. Similarly, a recent prospective study reported that lung function assessment in mid-life may identify individuals at greater risk of future cardiovascular disease.⁴⁵ Augmentation index could be non-invasively assessed at an early age in healthy subjects with impaired lung function who are still free of respiratory illnesses, and conversely, pulmonary function could be assessed in subjects with increased augmentation

Table 3 Bivariate family, age, sex, population corrected phenotypic correlations and 95% confidence intervals with or without smoking adjustment from a bivariate structural equation saturated model of a genetic covariance decomposition model between lung function and arterial stiffness parameters.

		Brachial Alx, %	Central Alx, %	Aortic PWV, m/s
Non smoking adjusted	FVC, % predicted	0.038 (–0.079, 0.156)	0.037 (–0.081, 0.155)	–0.030 (–0.145, 0.085)
	FEV ₁ , % predicted	0.011 (–0.107, 0.129)	0.009 (–0.109, 0.128)	–0.055 (–0.172, 0.061)
	FVC	–0.147* (–0.267, –0.027)	–0.150* (–0.271, –0.030)	0.000 (–0.120, 0.119)
	FEV ₁	–0.162* (–0.281, –0.043)	–0.166* (–0.285, –0.046)	–0.007 (–0.128, 0.115)
Smoking adjusted	FVC, % predicted	0.063 (–0.055, 0.181)	0.062 (–0.056, 0.180)	–0.017 (–0.134, 0.099)
	FEV ₁ , % predicted	0.040 (–0.078, 0.159)	0.039 (–0.080, 0.157)	–0.041 (–0.160, 0.077)
	FVC	–0.121 (–0.243, 0.001)	–0.123 (–0.246, –0.001)	0.012 (–0.108, 0.133)
	FEV ₁	–0.133* (–0.254, –0.012)	–0.126* (–0.246, –0.006)	0.009 (–0.114, 0.131)

Alx, augmentation index; PWV, pulse wave velocity; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 s.

**p* < 0.05.

indices or atherosclerotic phenotypes if further studies confirm our results. To our knowledge, no previous study has investigated the relationship between PWV and lung function in healthy subjects; nonetheless, other authors reported higher PWV in the case of impaired lung function in chronic respiratory diseases.^{37,39,43,44}

Our cohort consisted of healthy middle-aged individuals who may present endothelial dysfunction (increased Alx) but normal aortic PWV, which is mainly accelerated in advanced atherosclerosis in older age.⁴⁶ Of note, the mean aortic PWV value was not elevated in our sample. A correlation between impaired pulmonary function and elevated Alx but not with aortic PWV could be explained if our study population had subclinical atherosclerosis with increased Aix, which was not significant enough to result in increased aortic PWV. We suppose that this argument may serve as a possible interpretation for the discrepancy between the Alx and PWV findings. In addition, it must be noted that the statistical test (genetic covariance composition) traditionally calls for a large sampling in comparison to our sample size. This could be the reason why our results concerning the covariance analysis are not statistically significant.

The strength of our study is underpinned by the evaluation of all the lung function and arterial stiffness tests that were performed by the same trained researchers, with the same devices, on the same day. However, as in every human clinical study, there are unavoidable limitations. Data were pooled across countries to raise the power to identify genetic and environmental effects but no evidence of heterogeneity between states was detected.

In conclusion, our study was the first international twin study to investigate the possible genetic relationship between lung function and arterial stiffness. Our data suggest a phenotypic but not genetic link between lung function and peripheral vascular resistance (wave reflection). This relationship may explain the importance of inflammation, oxidative stress and hypoxia in the pathogenesis of atherogenesis. Improved understanding of the factors associated with increased cardiovascular risk in the setting of lung function impairment is needed. Our study could be a first step to find further associations of vascular changes in different airway diseases and help guide linkage studies toward better understanding of the cardiopulmonary system. Improved understanding of the factors associated with increased cardiovascular risk in the setting of lung function impairment is needed.

Financial/nonfinancial disclosures

We would like to acknowledge the support of Medexpert Ltd. for their continuous help during the study and the Twins Days Festival committee for their help with the American portion of the study. The research was also supported by the Balassi Institute - Hungarian Scholarship Board Office (Italian Institute of Culture) and Hungarian Scientific Research Fund [OTKA 68808]. We would like to acknowledge the help of Janos Osztoivits, MD, PhD and Stephen F. Luczek, MD. Furthermore, the help of Mrs. Daynere Vykoukal (Scientific Writer, The Methodist Hospital Research Institute, Methodist DeBakey Heart & Vascular Center, Houston, TX) in linguistic revision is highly acknowledged.

Other contributions

The paper was presented at 20th Annual meeting of European Respiratory Society in Barcelona in September, 2010 and chosen to be in the 'top 4' media news of the congress. Commenting on the results, ERS president Nikolaos Siafakas, MD, said "this is an important study that shows a link between lung diseases and the whole body." (Twin Study Suggests Common Mechanism Driving Lung Function and Arterial Stiffness, <http://www.medscape.com/viewarticle/729168>).

Author contributions

Dr Tarnoki DL: the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Tarnoki AD: the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Lazar: the conception and design of the study, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Mrs Medda: the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Mr Littvay: analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Mr Cotichini: the conception and design of the study, acquisition of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Mr Fagnani: acquisition of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Mrs Stazi: the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Nisticó: acquisition of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Lucatelli: analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Boatta: analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Zini: analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Fanelli: the conception and design of the study, analysis and interpretation of data, drafting the article or

revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Baracchini: the conception and design of the study, interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Meneghetti: the conception and design of the study, interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Prof Jermendy: interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Prof Preda: the conception and design of the study, interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Kiss: the conception and design of the study, interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Karlinger: the conception and design of the study, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Mrs Lannert: the conception and design of the study, analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Prof Schillaci: the conception and design of the study, interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Molnar: analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Dr Garami: the conception and design of the study, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Prof Berczi: the conception and design of the study, interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Prof Horvath: the conception and design of the study, analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted.

Conflict of interest

D. Tarnoki, A. Tarnoki and A. A. Molnar received travel reimbursements in order to perform the American measurements (Medexpert Ltd.). D. Tarnoki and A. Tarnoki received financial support for the equipment purchase by Balassi Institute - Hungarian Scholarship Board Office and Hungarian Scientific Research Fund [OTKA 68808]. Agnes Lannert is also an employee of Medexpert Ltd. Hungary, who provided the Arteriograph device (arterial stiffness and function measurement) for Drs. Tarnoki. Mrs. Lannert educated the investigators on the use of the device and

facilitated measurements as an application specialist. She also participated in the data analysis and manuscript preparation. Other authors declare no conflict of interest.

References

- Ingebrigtsen TS, Thomsen SF, van der Sluis S, Miller M, Christensen K, Sigsgaard T, et al. Genetic influences on pulmonary function: a large sample twin study. *Lung* 2011;**189**: 323–30.
- Hubert HB, Fabsitz RR, Feinleib M, Gwinn C. Genetic and environmental influences on pulmonary function in adult twins. *Am Rev Respir Dis* 1982;**125**:409–15.
- McClearn GE, Svartengren M, Pedersen NL, Heller DA, Plomin R. Genetic and environmental influences on pulmonary function in aging Swedish twins. *J Gerontol* 1994;**49**:264–8.
- Hukkinen M, Kaprio J, Broms U, Viljanen A, Kotz D, Rantanen T, et al. Heritability of lung function: a twin study among never-smoking elderly women. *Twin Res Hum Genet* 2011;**14**:401–7.
- Devor EJ, Crawford MH. Family resemblance for normal pulmonary function. *Ann Hum Biol* 1984;**11**:439–48.
- Hallberg J, Iliadou A, Anderson M, de Verdier MG, Nihlén U, Dahlbäck M, et al. Genetic and environmental influence on lung function impairment in Swedish twins. *Respir Res* 2010;**11**:92.
- Gottlieb DJ, Wilk JB, Harmon M, Evans JC, Joost O, Levy D, et al. Heritability of longitudinal change in lung function. The Framingham study. *Am J Respir Crit Care Med* 2001;**164**: 1655–9.
- Higgins MW, Keller JB. Predictors of mortality in the adult population of Tecumseh: respiratory symptoms, chronic respiratory disease, and ventilatory lung function. *Arch Environ Health* 1970;**21**:418–24.
- Tockman MS, Pearson JD, Fleg JL, Metter EJ, Kao SY, Rampal KG, et al. Rapid decline in FEV₁: a new risk factor for coronary heart disease mortality. *Am J Respir Crit Care Med* 1995;**151**:390–8.
- Brunner EJ, Shipley MJ, Witte DR, Singh-Manoux A, Britton AR, Tabak AG, et al. Arterial stiffness, physical function, and functional limitation: the whitehall ii study. *Hypertension* 2011;**57**:1003–9.
- Engström G, Lind P, Hedblad B, Wollmer P, Stavenow L, Janzon L, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. *Circulation* 2002;**106**:2555–60.
- Marcus EB, Curb JD, MacLean CJ, Reed DM, Yano K. Pulmonary function as a predictor of coronary heart disease. *Am J Epidemiol* 1989;**129**:97–104.
- Zureik M, Benetos A, Neukirch C, Courbon D, Bean K, Thomas F, et al. Reduced pulmonary function is associated with central arterial stiffness in men. *Am J Respir Crit Care Med* 2001;**164**: 2181–5.
- Heath AC, Nyholt DR, Neuman R, Madden PA, Buchholz KK, Todd RD, et al. Zygosity diagnosis in the absence of genotypic data: an approach using latent class analysis. *Twin Res* 2003;**6**: 22–6.
- Anonymous. American Thoracic Society/European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. *Am J Respir Crit Care Med* 2005;**171**:912–30.
- Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. *Eur Respir J* 2005;**26**:948–68.
- Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC, et al. Lung volumes and forced ventilatory flows. *Eur Respir J* 1993;**6**:5–40. ECCS/ERS.

18. Baulmann J, Schillings U, Rickert S, Uen S, Düsing R, Illyes M, et al. A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezo-electronic methods. *J Hypertens* 2008;**26**:523–8.
19. Horvath IG, Nemeth A, Lenkey Z, Alessandri N, Tufano F, Kis P, et al. Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity. *J Hypertens* 2010;**28**:2068–75.
20. Williams B. Pulse wave analysis and hypertension: evangelism versus skepticism. *J Hypertens* 2004;**22**:447–9.
21. O'Rourke MF, Nichols WW, Safar ME. Pulse waveform analysis and arterial stiffness: realism can replace evangelism and skepticism. *J Hypertens* 2004;**22**:1633–4.
22. Lim HE, Park CG, Shin SH, Ahn JC, Seo HS, Oh DJ. Aortic pulse wave velocity as an independent marker of coronary artery disease. *Blood Press* 2004;**13**:369–75.
23. Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. *Arterioscler Thromb Vasc Biol* 2001;**21**:2046–50.
24. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. *Circulation* 2006;**113**:664–70.
25. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation* 2006;**113**:1213–25.
26. Baulmann J, Homsy R, Uen S, Vetter H, Düsing R, Mengden T. Arterial stiffness in arterial hypertension – a novel risk factor for left ventricular hypertrophy and heart failure? *Dtsch Med Wochenschr* 2004;**129**:447–52.
27. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J* 2006;**27**:2588–605.
28. Muthén LK, Muthén BO. *Mplus user's guide*. ed. Los Angeles, CA: Muthén and Muthén; 1998–2010.
29. Bollen KA, Stine RA. Bootstrapping goodness-of-fit measures in structural equation models. *Sociological Methods Res* 1992;**20**:1:205–29.
30. Tarnoki AD, Tarnoki DL, Stazi MA, Medda E, Cotichini R, Nisticò L, et al. Heritability of central blood pressure and arterial stiffness: a twin study. *J Hypertens* 2012;**30**:1564–71.
31. Snieder H, Hayward CS, Perks U, Kelly RP, Kelly PJ, Spector TD. Heritability of central systolic pressure augmentation: a twin study. *Hypertension* 2000;**35**:574–9.
32. Ge D, Young TW, Wang X, Kapuku GK, Treiber FA, Snieder H. Heritability of arterial stiffness in black and white American youth and young adults. *Am J Hypertens* 2007;**20**:1065–72.
33. Cecelja M, Jiang B, McNeill K, Kato B, Ritter J, Spector T, et al. Increased wave reflection rather than central arterial stiffness is the main determinant of raised pulse pressure in women and relates to mismatch in arterial dimensions: a twin study. *J Am Coll Card* 2009;**54**:695–703.
34. Tarnoki AD, Tarnoki DL, Stazi MA, Medda E, Cotichini R, Lucatelli P, et al. Twins lead to the prevention of atherosclerosis. Preliminary findings of International twin study 2009. *J Vasc Ultras* 2011;**35**:61–71.
35. Brunner EJ, Shipley MJ, Witte DR, Singh-Manoux A, Britton AR, Tabak AG, et al. Arterial stiffness, physical function, and functional limitation: the Whitehall II Study. *Hypertension* 2011;**57**:1003–9.
36. Maclay JD, McAllister DA, Macnee W. Cardiovascular risk in chronic obstructive pulmonary disease. *Respirology* 2007;**12**:634–41.
37. Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, et al. Vascular dysfunction in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2009;**180**:513–20.
38. Janner JH, McAllister DA, Godtfredsen NS, Prescott E, Vestbo J. Is chronic obstructive pulmonary disease associated with increased arterial stiffness? *Respir Med* 2012;**106**:397–405.
39. Nevzorova VA, Shekunova OI, Brodskaja TA. Aortic stiffness in chronic obstructive pulmonary disease concurrent with ischemic heart disease. *Ter Arkh* 2010;**82**:18–22.
40. Dransfield MT, Huang F, Nath H, Singh SP, Bailey WC, Washko GR. CT emphysema predicts thoracic aortic calcification in smokers with and without COPD. *COPD* 2010;**7**:404–10.
41. Malerba M, Romanelli G. Early cardiovascular involvement in chronic obstructive pulmonary disease. *Monaldi Arch Chest Dis* 2009;**71**:59–65.
42. Arunachalam G, Sundar IK, Hwang JW, Yao H, Rahman I. Emphysema is associated with increased inflammation in lungs of atherosclerosis-prone mice by cigarette smoke: implications in comorbidities of COPD. *J Inflamm (Lond)* 2010;**7**:34.
43. McAllister DA, Maclay JD, Mills NL, Mair G, Miller J, Anderson D, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2007;**176**:1208–14.
44. Weiler Z, Zeldin Y, Magen E, Zamir D, Kidon MI. Pulmonary function correlates with arterial stiffness in asthmatic patients. *Respir Med* 2010;**104**:197–203.
45. Bolton CE, Cockcroft JR, Sabit R, Munnery M, McEnery CM, Wilkinson IB, et al. Lung function in mid-life compared with later life is a stronger predictor of arterial stiffness in men: the Caerphilly Prospective Study. *Int J Epidemiol* 2009;**38**:867–76.
46. Kelly R, Hayward C, Avolio A, O'Rourke M. Noninvasive determination of age-related changes in the human arterial pulse. *Circulation* 1989;**80**:1652–9.